Results 241 to 250 of about 1,252,407 (298)

TIR-domain-containing protein C as modulator of innate immune checkpoints. [PDF]

Sci Rep
Heine L, Griffiths H, Hu H, Müller I, Kuhn S, Rudolph L, Rait X, Waldhuber A, Chen Y, Miethke T.   +9 more
europepmc   +1 more source

Transferrin Receptor Overexpression in Solid Tumors Is Associated with Inflamed Microenvironments and Upregulated Immune Checkpoints, with Implications for Immunotherapy Sensitivity. [PDF]

Cancers (Basel)
Trabolsi A, Lekakis M, Commisso PM, Gandhi N, Elliott A, Liu SV, Ma PC, Hoon DSB, Wei S, Antonarakis ES, Antonarakis ES, Arumov A, Schatz JH.   +12 more
europepmc   +1 more source

Elevated expression of immune checkpoints and pro-inflammatory cytokines as potential biomarkers in pediatric Vulvar Lichen Sclerosus. [PDF]

Sci Rep
Grywalska E, Mertowska P, Mertowski S, Zaborek-Łyczba M, Łyczba J, Woźniakowska E, Rasoul-Pelińska K, Ćwik K, Torres A.   +8 more
europepmc   +1 more source

Editorial: Immune checkpoints regulatory mechanisms and immunotherapy strategies in gastrointestinal tumors. [PDF]

Front Oncol
Xi Q, Zhang R.
europepmc   +1 more source

Beyond Negative Regulation: IL-1R8 and IL-1R2 as Novel Immune Checkpoints. [PDF]

Eur J Immunol
Supino D, Garuti R, Garlanda C.
europepmc   +1 more source

Multiplex profiling of 16 immune checkpoints identifies novel serum biomarker panels for breast cancer detection and TNBC stratification: A case-control study. [PDF]

PLoS One
Stayoussef M, Habel A, Xu W, Bessaad M, Bouaziz H, Ayadi M, Almawi WY, Larbi A, Yacoubi-Loueslati B.   +8 more
europepmc   +1 more source

Immune Checkpoint Inhibitors in Melanoma [PDF]

Lancet, The, 2021
Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and anti-PD-1 antibodies, have revolutionised the management of many cancers, particularly advanced melanoma, for which tumour regression and long-term durable cancer control ...
James Larkin, Georgina V. Long
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Immune Checkpoint Blockade

Hematology/Oncology Clinics of North America, 2014
Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs.
Jarushka, Naidoo, David B, Page, Jedd D, Wolchok   +2 more
openaire   +2 more sources

Immune Checkpoint Inhibitors in the Aged

Current Oncology Reports, 2021
Large phase III trials have established the benefit of checkpoint blockade across multiple tumor types, but patient representation is limited in some subgroups including the aged population. There are several changes in the immune system that occur with age (termed immunosenescence) that could potentially limit efficacy in aged populations.Despite the ...
James Isaacs, Scott Antonia, Jeffrey Clarke   +2 more
openaire   +2 more sources